| Project/Area Number |
26461159
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Respiratory organ internal medicine
|
|---|
| Research Institution | Tottori University |
|---|
Principal Investigator |
SHIMIZU EIJI 鳥取大学, 医学部, 教授 (50187449)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
高田 美也子 鳥取大学, 医学部, プロジェクト研究員 (50523643)
千酌 浩樹 鳥取大学, 医学部附属病院, 教授 (90283994)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
YAMAGUCHI Kousuke 鳥取大学, 医学部附属病院, 助教 (60529402)
MIYAKE Naomi 鳥取大学, 医学部, 特任教員 (90747205)
|
|---|
| Project Period (FY) |
2014-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2016: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2015: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2014: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | 悪性胸膜中皮腫 / ペメトレキセド / 臨床呼吸器学 / 胸膜中皮腫 / 耐性 |
|---|
| Outline of Final Research Achievements |
Pemetrexed is used as chemotherapy of the malignant pleural mesothelioma, however, the resistance for pemetrexed is now increasing problem. Therefore, we made pemetrexed-resistant cell lines. Using these cell lines, we searched for the resistant related molecules and pathways and a new clinical cure to overcome pemetrexed resistance. As a result, we found that increasment of the expression of Akt in resistant cell lines. Finally, for a conquest cure for the resistance, we demonstrated that the combination therapy of pemetrexed and BEZ235 has significant antitumor effect for the premetrexed resistant cell lines, and that this combination is potential promising therapy to overcome pemetrexed resistance in malignant pleural mesothelioma.
|
